Agilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea

Reuters

2025/05/14

Agilent Technologies Inc. Enters Partnership with Ubix <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Advance Cancer Research in South Korea

**Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc. $(A)$ has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation $(TPD.AU)$ and antibody-drug conjugate $(ADC)$ therapies. The partnership combines Ubix's Degraducer® anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535026035"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535026035\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535026035?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 06:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535026035","market":"nz","top_or_hot":-1,"title":"Agilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agilent Technologies Inc. Enters Partnership with Ubix <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Advance Cancer Research in South Korea\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc. <a href=\"https://laohu8.com/S/A\">$(A)$</a> has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation <a href=\"https://laohu8.com/S/TPD.AU\">$(TPD.AU)$</a> and antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> therapies. The partnership combines Ubix's Degraducer® anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-14 06:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agilent Technologies Inc. Enters Partnership with Ubix <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Advance Cancer Research in South Korea\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc. <a href=\"https://laohu8.com/S/A\">$(A)$</a> has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation <a href=\"https://laohu8.com/S/TPD.AU\">$(TPD.AU)$</a> and antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> therapies. The partnership combines Ubix's Degraducer® anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科學工具和服務","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL360lQF:1","article_id":"2535026035","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535026035","pubTimestamp":1747175153,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"**Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc.  has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation  and antibody-drug conjugate  therapies. The partnership combines Ubix's Degraducer anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU2041044095.USD":"Blackrock Circular Economy A2 USD","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","A":"安捷伦科技","BK4585":"ETF&股票定投概念","LU1543694498.USD":"法巴水资源基金RH MD Dis","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU0347712357.USD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (USD) ACC","LU2089279066.USD":"ALLIANZ GLOBAL WATER \"AT\" (USD) ACC","LU2413666426.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (HKD) ACC","LU1721428933.USD":"法巴全球经典环境基金RH MD Dis","LU2413666699.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"CRH\" (HKDHDG) INC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4588":"碎股","BK4567":"ESG概念","LU2229751404.USD":"ALLIANZ GLOBAL WATER \"AT3\" (USD) ACC","LU1165135440.EUR":"BNP Paribas Aqua Classic Cap EUR"},"translate_title":"安捷伦科技公司与Ubix Therapeutics合作推进韩国癌症研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A":0.9},"content_text":"Agilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea\n    \n\n        **Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc. $(A)$ has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation $(TPD.AU)$ and antibody-drug conjugate $(ADC)$ therapies. The partnership combines Ubix's Degraducer® anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}